Bykowska K, Letowska M, Sabliński J, Binder B R, Kopeć M, Lopaciuk S
Laboratory of Blood Coagulation and Hemostasis, Institute of Hematology and Blood Transfusion, Warsaw.
Acta Haematol Pol. 1994;25(3):261-8.
The aim of this study was to compare the secretory response of the vascular wall in vivo to DDAVP (i.v. 0.3 microgram/kg, 30 min) and to venous occlusion (VO, 20 min) in control healthy subjects, patients with von Willebrand's disease type I (vWd I) and patients with von Willebrand's disease type III (vWd III). In controls (n = 10) and vWd I (n = 12), DDAVP induced a 2 to 3-fold rise in plasma von Willebrand factor antigen (vWf: Ag), factor VIII coagulant activity (VIII: C) and tissue--type plasminogen activator antigen (t-PA:Ag). VO was less effective in increasing vWf: Ag and VIII:C but produced a greater rise in t-PA:Ag. Large increments (over 10-fold) were observed in plasmin-alpha 2-antiplasmin complexes following both stimuli. In vWd III (n = 10), DDAVP and VO failed to increase vWf:Ag, VIII:C and t-PA:Ag. No significant changes in plasmin-alpha 2-antiplasmin complexes were observed in this group. Moreover, the baseline t-PA:Ag values were significantly lower in vWd III (2.17 +/- 1.13 ng/ml) than in controls (4.84 +/- 1.97 ng/ml, p < 0.001). A significant increase in urokinase--type plasminogen activator antigen (u-PA:Ag) was found only in controls after VO. Neither controls nor patients with vWd showed any changes in plasma fibronectin levels following DDAVP. The low t-PA:Ag results and the abnormal fibrinolytic response to DDAVP and VO in patients with severe (type III) vWd indicate that their endothelial cell abnormality is more extensive than the defect in the synthesis or release of vWf.
本研究的目的是比较在对照健康受试者、I型血管性血友病(vWd I)患者和III型血管性血友病(vWd III)患者体内,血管壁对去氨加压素(静脉注射0.3微克/千克,30分钟)和静脉阻塞(VO,20分钟)的分泌反应。在对照组(n = 10)和vWd I组(n = 12)中,去氨加压素使血浆血管性血友病因子抗原(vWf:Ag)、凝血因子VIII促凝活性(VIII:C)和组织型纤溶酶原激活物抗原(t-PA:Ag)升高2至3倍。VO在增加vWf:Ag和VIII:C方面效果较差,但使t-PA:Ag升高幅度更大。在两种刺激后,纤溶酶-α2-抗纤溶酶复合物均有大幅增加(超过10倍)。在vWd III组(n = 10)中,去氨加压素和VO未能增加vWf:Ag、VIII:C和t-PA:Ag。该组中纤溶酶-α2-抗纤溶酶复合物未观察到显著变化。此外,vWd III组的基线t-PA:Ag值(2.17±1.13纳克/毫升)显著低于对照组(4.84±1.97纳克/毫升,p < 0.001)。仅在对照组中,VO后尿激酶型纤溶酶原激活物抗原(u-PA:Ag)显著增加。去氨加压素后,对照组和vWd患者的血浆纤连蛋白水平均未显示任何变化。重度(III型)vWd患者的低t-PA:Ag结果以及对去氨加压素和VO的异常纤溶反应表明,他们的内皮细胞异常比vWf合成或释放缺陷更为广泛。